MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318785 | Name: Tacrine
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tacrine is a centrally acting anticholinesterase and indirect cholinergic agonist. It is approved for the treatment of Alzheimer's disease.

Chemical Structure

Tacrine
Tacrine
CAS#321-64-2

Theoretical Analysis

MedKoo Cat#: 318785

Name: Tacrine

CAS#: 321-64-2

Chemical Formula: C13H14N2

Exact Mass: 198.1157

Molecular Weight: 198.27

Elemental Analysis: C, 78.75; H, 7.12; N, 14.13

Price and Availability

Size Price Availability Quantity
1g USD 250.00
2g USD 450.00
5g USD 650.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
CS 12602, CS 12602, CS 12602, Tacrine, Tacrinum, Tetrahydroaminocrine
IUPAC/Chemical Name
1,2,3,4-tetrahydroacridin-9-amine
InChi Key
YLJREFDVOIBQDA-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)
SMILES Code
NC1=C(CCCC2)C2=NC3=CC=CC=C31
Appearance
White to off-white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 198.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ismaili L, Refouvelet B, Benchekroun M, Brogi S, Brindisi M, Gemma S, Campiani G, Filipic S, Agbaba D, Esteban G, Unzeta M, Nikolic K, Butini S, Marco-Contelles J. Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. Prog Neurobiol. 2016 Jan 18. pii: S0301-0082(15)00162-8. doi: 10.1016/j.pneurobio.2015.12.003. [Epub ahead of print] Review. PubMed PMID: 26797191. 2: Minarini A, Milelli A, Simoni E, Rosini M, Bolognesi ML, Marchetti C, Tumiatti V. Multifunctional tacrine derivatives in Alzheimer's disease. Curr Top Med Chem. 2013;13(15):1771-86. Review. PubMed PMID: 23931443. 3: Romero A, Cacabelos R, Oset-Gasque MJ, Samadi A, Marco-Contelles J. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease. Bioorg Med Chem Lett. 2013 Apr 1;23(7):1916-22. doi: 10.1016/j.bmcl.2013.02.017. Epub 2013 Feb 16. Review. PubMed PMID: 23481643. 4: Korábečný J, Spilovská K, Benek O, Musílek K, Soukup O, Kuča K. [Tacrine and its derivatives in the therapy of Alzheimers disease]. Ceska Slov Farm. 2012 Oct;61(5):210-21. Review. Czech. PubMed PMID: 23256654. 5: de Aquino RA, Modolo LV, Alves RB, de Fatima A. Design of new drugs for the treatment of Alzheimer's disease based on tacrine structure. Curr Drug Targets. 2013 Mar;14(3):378-97. Review. PubMed PMID: 23176115. 6: Tumiatti V, Minarini A, Bolognesi ML, Milelli A, Rosini M, Melchiorre C. Tacrine derivatives and Alzheimer's disease. Curr Med Chem. 2010;17(17):1825-38. Review. PubMed PMID: 20345341. 7: Jogani VV, Shah PJ, Mishra P, Mishra AK, Misra AR. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis Assoc Disord. 2008 Apr-Jun;22(2):116-24. doi: 10.1097/WAD.0b013e318157205b. Review. PubMed PMID: 18525282. 8: Patocka J, Jun D, Kuca K. Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer's disease. Curr Drug Metab. 2008 May;9(4):332-5. Review. PubMed PMID: 18473751. 9: Li WM, Kan KK, Carlier PR, Pang YP, Han YF. East meets West in the search for Alzheimer's therapeutics - novel dimeric inhibitors from tacrine and huperzine A. Curr Alzheimer Res. 2007 Sep;4(4):386-96. Review. PubMed PMID: 17908041. 10: Qizilbash N, Birks J, Lopez Arrieta J, Lewington S, Szeto S. WITHDRAWN: Tacrine for Alzheimer's disease. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD000202. Review. PubMed PMID: 17636619. 11: Summers WK. Tacrine, and Alzheimer's treatments. J Alzheimers Dis. 2006;9(3 Suppl):439-45. Review. PubMed PMID: 16914883. 12: Arrieta JL, Artalejo FR. Methodology, results and quality of clinical trials of tacrine in the treatment of Alzheimer's disease: a systematic review of the literature. Age Ageing. 1998 Mar;27(2):161-79. Review. PubMed PMID: 16296676. 13: Camps P, Muñoz-Torrero D. Tacrine-huperzine A hybrids (huprines): a new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. Mini Rev Med Chem. 2001 Jul;1(2):163-74. Review. PubMed PMID: 12369981. 14: Qizilbash N, Birks J, Lopez Arrieta J, Lewington S, Szeto S. Tacrine for Alzheimer's disease. Cochrane Database Syst Rev. 2000;(3):CD000202. Review. Update in: Cochrane Database Syst Rev. 2007;(3):CD000202. PubMed PMID: 10908463. 15: Qizilbash N, Birks J, López-Arrieta J, Lewington S, Szeto S. Tacrine for Alzheimer's disease. Cochrane Database Syst Rev. 2000;(2):CD000202. Review. Update in: Cochrane Database Syst Rev. 2000;(3):CD000202. PubMed PMID: 10796507. 16: Proctor GR, Harvey AL. Synthesis of tacrine analogues and their structure-activity relationships. Curr Med Chem. 2000 Mar;7(3):295-302. Review. PubMed PMID: 10637366. 17: Kurz A. The therapeutic potential of tacrine. J Neural Transm Suppl. 1998;54:295-9. Review. PubMed PMID: 9850938. 18: Giacobini E. Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochem Int. 1998 May-Jun;32(5-6):413-9. Review. PubMed PMID: 9676739. 19: Conway EL. A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease: methodologic considerations. Clin Neuropharmacol. 1998 Jan-Feb;21(1):8-17. Review. PubMed PMID: 9579280. 20: Ventura M, Sternon J. [Therapeutic results: tacrine]. Rev Med Brux. 1997 Dec;18(6):394-7. Review. French. PubMed PMID: 9481161.